Skip to main content
In stock | Targeted Therapy

Olverembatinib

Oncology Type Hematologic (Leukemia)
Drug Class / Mechanism BCR-ABL Tyrosine Kinase Inhibitor
No Image
Description

Olverembatinib is classified as a BCR-ABL Tyrosine Kinase Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy
Oncology Type Hematologic (Leukemia)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3